ACR appropriateness criteria ® ductal carcinoma in situ

Breast Journal

Volumn 18, Issue 1, 2012, Pages 8-15

  Moran, Meena S ^a   Bai, Harrison X ^a   Harris, Eleanor E R ^b   Arthur, Douglas W ^c   Bailey, Lisa ^d,e   Bellon, Jennifer R ^f   Carey, Lisa ^g,h   Goyal, Sharad ⁱ   Halyard, Michele Y ^j   Horst, Kathleen C ^k   MacDonald, Shannon M ^l   Haffty, Bruce G ⁱ  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Summitt Medical Center   (United States)

^e AMERICAN COLLEGE OF SURGEONS   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g UNIVERSITY OF NORTH CAROLINA   (United States)

^h AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

ⁱ ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^j MAYO CLINIC   (United States)

^k STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l MASSACHUSETTS GENERAL HOSPITAL   (United States)

more..

Author keywords

ACR appropriateness criteria; breast conservation therapy; ductal carcinoma in situ; guidelines; radiation therapy

Indexed keywords

ANASTROZOLE; TAMOXIFEN; TRASTUZUMAB;

ACCELERATED PARTIAL BREAST RADIATION; ARTICLE; CANCER RADIOTHERAPY; CONSENSUS DEVELOPMENT; HUMAN; INTRADUCTAL CARCINOMA; MASTECTOMY; MEDICAL LITERATURE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTIAL MASTECTOMY; PEER REVIEW; PRACTICE GUIDELINE;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MASTECTOMY; MASTECTOMY, SEGMENTAL; NEOPLASM RECURRENCE, LOCAL; TAMOXIFEN;

EID: 84855709795     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/j.1524-4741.2011.01197.x     Document Type: Article

References (37)

1. Fisher B, Dignam J, Wolmark N, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 1998; 16: 441-52. (Pubitemid 28135585)
2. Fisher B, Land S, Mamounas E, Dignam J, Fisher ER, Wolmark N,. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the national surgical adjuvant breast and bowel project experience. Semin Oncol 2001; 28: 400-18. (Pubitemid 32762083)
3. Fisher ER, Costantino J, Fisher B, Palekar AS, Redmond C, Mamounas E,. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. Intraductal carcinoma (ductal carcinoma in situ). The National Surgical Adjuvant Breast and Bowel Project Collaborating Investigators. Cancer 1995; 75: 1310-9.
4. Bijker N, Peterse JL, Duchateau L, et al. Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol 2001; 19: 2263-71. (Pubitemid 32366979)
5. Emdin SO, Granstrand B, Ringberg A, et al. SweDCIS: radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results of a randomised trial in a population offered mammography screening. Acta Oncol 2006; 45: 536-43. (Pubitemid 44167203)
6. Houghton J, George WD, Cuzick J, Duggan C, Fentiman IS, Spittle M,. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 2003; 362: 95-102. (Pubitemid 36831018)
7. Julien JP, Bijker N, Fentiman IS, et al. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Lancet 2000; 355: 528-33. (Pubitemid 30088672)
8. Fisher ER, Leeming R, Anderson S, Redmond C, Fisher B,. Conservative management of intraductal carcinoma (DCIS) of the breast. Collaborating NSABP investigators. J Surg Oncol 1991; 47: 139-47.
9. Silverstein MJ, Cohlan BF, Gierson ED, et al. Duct carcinoma in situ: 227 cases without microinvasion. Eur J Cancer 1992; 3: 630-4.
10. Solin LJ, Fourquet A, Vicini FA, et al. Long-term outcome after breast-conservation treatment with radiation for mammographically detected ductal carcinoma in situ of the breast. Cancer 2005; 103: 1137-46. (Pubitemid 40328083)
11. Solin LJ, Kurtz J, Fourquet A, et al. Fifteen-year results of breast-conserving surgery and definitive breast irradiation for the treatment of ductal carcinoma in situ of the breast. J Clin Oncol 1996; 14: 754-63. (Pubitemid 26085518)
12. Bijker N, Meijnen P, Peterse JL, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853 - a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 2006; 24: 3381-7. (Pubitemid 46638893)
13. Silverstein MJ, Lagios MD, Groshen S, et al. The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med 1999; 340: 1455-61. (Pubitemid 29220544)
14. Silverstein MJ,. The University of Southern California/Van Nuys prognostic index for ductal carcinoma in situ of the breast. Am J Surg 2003; 186: 337-43. (Pubitemid 38368606)
15. Wong JS, Kaelin CM, Troyan SL, et al. Prospective study of wide excision alone for ductal carcinoma in situ of the breast. J Clin Oncol 2006; 24: 1031-6. (Pubitemid 46638798)
16. Hughes LL, Wang M, Page DL, et al. Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2009; 27: 5319-24.
17. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999; 353: 1993-2000. (Pubitemid 29271743)
18. Allred DC, Brown P, Medina D,. The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer. Breast Cancer Res 2004; 6: 240-5. (Pubitemid 39440252)
19. Wapnir I, Dignam J, Fisher B,. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst 2011; 103: 478-88.
20. Moran CJ, Kell MR, Flanagan FL, Kennedy M, Gorey TF, Kerin MJ,. Role of sentinel lymph node biopsy in high-risk ductal carcinoma in situ patients. Am J Surg 2007; 194: 172-5. (Pubitemid 47008975)
21. Meijnen P, Oldenburg HS, Loo CE, Nieweg OE, Peterse JL, Rutgers EJ,. Risk of invasion and axillary lymph node metastasis in ductal carcinoma in situ diagnosed by core-needle biopsy. Br J Surg 2007; 94: 952-6. (Pubitemid 47236538)
22. Yi M, Krishnamurthy S, Kuerer HM, et al. Role of primary tumor characteristics in predicting positive sentinel lymph nodes in patients with ductal carcinoma in situ or microinvasive breast cancer. Am J Surg 2008; 196: 81-7. (Pubitemid 351847763)
23. Lara JF, Young SM, Velilla RE, Santoro EJ, Templeton SF,. The relevance of occult axillary micrometastasis in ductal carcinoma in situ: a clinicopathologic study with long-term follow-up. Cancer 2003; 98: 2105-13. (Pubitemid 37392413)
24. Dominguez FJ, Golshan M, Black DM, et al. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ. Ann Surg Oncol 2008; 15: 268-73.
25. Parikh R, Haffty BG, Lannin D, Moran MS,. Ductal carcinoma in situ with microinvasion: prognostic implications, long-term outcomes, and role of axillary evaluation. Int J Radiat Oncol Biol Phys 2010. [Epub ahead of print].
26. Solin LJ, Fowble BL, Yeh IT, et al. Microinvasive ductal carcinoma of the breast treated with breast-conserving surgery and definitive irradiation. Int J Radiat Oncol Biol Phys 1992; 23: 961-8.
27. Intra M, Veronesi P, Mazzarol G, et al. Axillary sentinel lymph node biopsy in patients with pure ductal carcinoma in situ of the breast. Arch Surg 2003; 138: 309-13. (Pubitemid 36292666)
28. Hughes KS, Schnaper LA, Cirrincione C, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 or older with early breast cancer. J Clin Oncol 2010; 28: 15s. 2010 (suppl; abstr 507).
29. Bazzocchi M, Zuiani C, Panizza P, et al. Contrast-enhanced breast MRI in patients with suspicious microcalcifications on mammography: results of a multicenter trial. AJR 2006; 186: 1723-32. (Pubitemid 46112539)
30. Kuhl CK, Schrading S, Bieling HB, et al. MRI for diagnosis of pure ductal carcinoma in situ: a prospective observational study. Lancet 2007; 370: 485-92. (Pubitemid 47214635)
31. Santamaria G, Velasco M, Farrus B, Zanon G, Fernandez PL,. Preoperative MRI of pure intraductal breast carcinoma - a valuable adjunct to mammography in assessing cancer extent. Breast 2008; 17: 186-94. (Pubitemid 351467956)
32. Schouten van der Velden AP, Boetes C, Bult P, Wobbes T,. The value of magnetic resonance imaging in diagnosis and size assessment of in situ and small invasive breast carcinoma. Am J Surg 2006; 192: 172-8. (Pubitemid 44066305)
33. Estevez LG, Alvarez I, Segui MA, et al. Current perspectives of treatment of ductal carcinoma in situ. Cancer Treat Rev 2010; 36: 507-17.
34. Vicini F, Beitsch P, Quiet C, et al. Five-year analysis of treatment efficacy and cosmesis by the American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry Trial in patients treated with accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys 2011; 79: 808-17.
35. Smith BD, Arthur DW, Buchholz TA, et al. Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys 2009; 74: 987-1001.
36. Polgar C, Van Limbergen E, Potter R, et al. Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery: recommendations of the Groupe Europeen de Curietherapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009). Radiother Oncol 2010; 94: 264-73.
37. Smith BD, Bentzen SM, Correa CR, et al. Fractionation for Whole Breast Irradiation: an American Society for Radiation Oncology (ASTRO) Evidence-Based Guideline. Int J Radiat Oncol Biol Phys 2011; 81: 59-68.